Bioresorbable scaffolds in the treatment of coronary artery disease

Zhang, Yaojun; Bourantas, Christos V.; Farooq, Vasim; Muramatsu, Takashi; Diletti, Roberto; Onuma, Yoshinobu; García‐García, Héctor M.; Serruys, Patrick W.

doi:10.2147/mder.s22547

Cited by 15 publications

(12 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Absorb scaffold offers several theoretical advantages over permanent metallic caging of the vessels. 13 , 14 Temporary scaffolding allows long-term restoration of endothelial structure and function. It does not affect a possible future surgical coronary revascularization.…”

Section: Absorb Bvs™ Design and Technologymentioning

confidence: 99%

Bioresorbable vascular scaffolds technology: current use and future developments

Giacchi

Ortega‐Paz

Brugaletta

et al. 2016

MDER

View full text Add to dashboard Cite

Coronary bioresorbable vascular scaffolds are a new appealing therapeutic option in interventional cardiology. The most used and studied is currently the Absorb BVS™. Its backbone is made of poly-L-lactide and coated by a thin layer of poly-D,L-lactide, it releases everolimus and is fully degraded to H2O and CO2 in 2–3 years. Absorb BVS™ seems to offer several theoretical advantages over metallic stent, as it gives temporary mechanical support to vessel wall without permanently caging it. Therefore, long-term endothelial function and structure are not affected. A possible future surgical revascularization is not compromised. Natural vasomotion in response to external stimuli is also recovered. Several observational and randomized trials have been published about BVS clinical outcomes. The main aim of this review is to carry out a systematic analysis about Absorb BVS™ studies, evaluating also the technical improvements of the Absorb GT1 BVS™.

show abstract

Section: Absorb Bvs™ Design and Technologymentioning

confidence: 99%

Bioresorbable vascular scaffolds technology: current use and future developments

Giacchi

Ortega‐Paz

Brugaletta

et al. 2016

MDER

View full text Add to dashboard Cite

show abstract

“…Presently, there are over 14 different biodegradable stents (BDS) which are in preclinical and clinical testing worldwide 36 . Two of these stent types are used in clinical practice and have already attained their Conformité Européenne (CE) mark; the Absorb Bioresorbable Vascular Scaffold (BVS) (Abbott Vascular) for coronary artery disease and the Igaki-Tamai® stent (Kyoto Medical Planning Co., Ltd.) for peripheral vascular disease.…”

Section: Bioabsorbable Stents: Current Statusmentioning

confidence: 99%

“…For instance, hot extruded Mg-Ca alloy has an improved strength and ductility combination, with a tensile strength reaching 240 MPa with 11% elongation 38 . Presently and to the best of the authors' knowledge, all but one Mg-based and Fe-based coronary BDS are still undergoing preclinical trials, with one Mg-based BDS (the DREAMS 1.0 scaffold) having already entered clinical trials 36 , 38 . As for non-coronary applications, metallic BDS has previously been studied in the treatment of infrapopliteal artery lesions 41 .…”

Section: Dissolvable Metallic Stentsmentioning

confidence: 99%

Bioabsorbable Stent Quo Vadis: A Case for Nano-Theranostics

Gundogan¹,

Tan²,

Farhatnia³

et al. 2014

Theranostics

View full text Add to dashboard Cite

Percutaneous coronary intervention (PCI) is one of the most commonly performed invasive medical procedures in medicine today. Since the first coronary balloon angioplasty in 1977, interventional cardiology has seen a wide array of developments in PCI. Bare metal stents (BMS) were soon superseded by the revolutionary drug-eluting stents (DES), which aimed to address the issue of restenosis found with BMS. However, evidence began to mount against DES, with late-stent thrombosis (ST) rates being higher than that of BMS. The bioabsorbable stent may be a promising alternative, providing vessel patency and support for the necessary time required and thereafter degrade into safe non-toxic compounds which are reabsorbed by the body. This temporary presence provides no triggers for ST, which is brought about by non-endothelialized stent struts and drug polymers remaining in vivo for extended periods of time. Likewise, nano-theranostics incorporated into a bioabsorbable stent of the future may provide an incredibly valuable single platform offering both therapeutic and diagnostic capabilities. Such a stent may allow delivery of therapeutic particles to specific sites thus keeping potential toxicity to a minimum, improved ease of tracking delivery in vivo by embedding imaging agents, controlled rate of therapy release and protection of the implanted therapy. Indeed, nanocarriers may allow an increased therapeutic index as well as offer novel post-stent implantation imaging and diagnostic methods for atherosclerosis, restenosis and thrombosis. It is envisioned that a nano-theranostic stent may well form the cornerstone of future stent designs in clinical practice.

show abstract

“…12 In this trial, 23 lesions in 23 patients were serially imaged by OCT post procedure and at 6 and 24 months (Cohort B1), and 19 lesions in 18 patients were serially investigated post procedure and at 12 and 36 months (Cohort B2). 11 Per study protocol, all patients were treated uniformly with a 3×18 mm BVS. To avoid variation in light intensity because of different types of the light imaging system used (ie, time-domain OCT [TD-OCT] vs. frequency-domain OCT [FD-OCT]), cases of investigation by TD-OCT were excluded from the analysis (n=12).…”

Section: Study Populationmentioning

confidence: 99%

“…Light Intensity Analysis of Bioresorbable Scaffolds analysis, to demonstrate the reproducibility of the assessment and to apply the method in serial OCT images collected post procedure and at 6, 12, 24 and 36 months follow-up in the ABSORB cohort B studies. 11 …”

mentioning

confidence: 99%